Genitourinary cancers include prostate, bladder, kidney, and testicular cancers, with diagnosis involving imaging and biopsy. Treatment is personalized, involving surgery, radiation, chemotherapy, ...

Fotivda monotherapy may match or outperform combination therapy in metastatic renal cell carcinoma, offering comparable progression-free survival and objective response rates. The 2025 ASCO Annual ...

More than 20 abstracts span Pfizer’s leading genitourinary cancer portfolio of approved standards of care and growing pipeline across prostate and bladder cancers Detailed overall survival (OS) ...

Donna Hansel, MD, PhD, of University of California, San Diego, School of Medicine, explains her use of human bladder cancer cells in her research. Having numerous therapies to treat prostate cancer ...

Contemporary outcomes of nephrectomy with IVC thrombectomy: Analysis from a large multi-institutional database. Metastatic progression and toxicity in high-risk clear cell renal cell carcinoma ...

Late-breaking KEYNOTE-B15 data show KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival and pathologic complete response rates ...

Toni K. Choueiri, MD, director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, presents findings from the phase 3 LITESPARK-022 study at the 2026 American Society of ...

Experts from around the world will gather in San Francisco for the 2026 ASCO Genitourinary Cancers Symposium (ASCO GU 2026), which will be held February 26 to February 28. Here, Drs Benjamin Croll and ...

Enfortumab vedotin and pembrolizumab combination shows a 49% reduction in mortality risk for advanced bladder cancer compared to chemotherapy. ASCO GU symposium focuses on antibody-drug conjugates, ...

This study validated PROSTOX as predicting radiotherapy-induced genitourinary toxicity, which can be differentiated into acute and chronic with mirSNP-based signatures, in patients with prostate ...

Traditionally, the evolutionary perspective of cancer has been understood as gradual alterations in passenger/driver genes that lead to branching phylogeny. However, in cases of prostate ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present the latest results from its leading genitourinary (GU) portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) ...